<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00518479</url>
  </required_header>
  <id_info>
    <org_study_id>PG/03/001</org_study_id>
    <nct_id>NCT00518479</nct_id>
  </id_info>
  <brief_title>Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression</brief_title>
  <official_title>Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leeds Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leeds</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uncontrolled high blood pressure can cause heart muscle 'thickening', and this increases the
      likelihood of complications and death. The high blood pressure explains some but not all of
      this increase in heart size. This study will investigate the other causes, and will measure
      the heart muscle 'thickness' very accurately using the latest and most accurate technique
      called cardiac magnetic resonance imaging (MRI). The best way to treat this heart thickening
      remains to be determined. We hope to be able to show that by specifically targeting the cause
      of heart muscle thickening we can reduce its occurrence more effectively than by other
      standard means of blood pressure treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is decrease in LV mass as assessed by cardiac MRI compared between the two treatment groups.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Hypertension</condition>
  <condition>Left Ventricular Hypertrophy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neurohormonal stimulatory arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neurohormonal inhibitory arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 160mg OD; Moxonidine 400mcg OD</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recently diagnosed essential hypertension (within 6 months).

          -  Age 25 to 80 years; Weight &lt; 100kg.

          -  Sinus rhythm without significant ventricular or atrial ectopy.

        Exclusion Criteria:

          -  Current angiotensin II receptor antagonist or ACE Inhibitor treatment.

          -  Contra-indication to any of the protocol anti-hypertensive agents.

          -  Angina requiring treatment with a Beta blocker or calcium antagonist

          -  Any disease affecting the autonomic nervous system e.g. congestive cardiac failure,
             diabetes, neurological disease, malignancy, pregnancy.

          -  Contraindication to MRI (pacemaker, intra-orbital debris, intra-auricular implants,
             intra-cranial clips, history of claustrophobia, inability to lie supine for 15 minutes
             etc).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Greenwood, MBChB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leeds University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leeds Teaching Hospital NHS Trust</name>
      <address>
        <city>Leeds</city>
        <state>Wesst Yorkshire</state>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.cmr-leeds.com/</url>
    <description>Cardiac MRI Research Group - Leeds, UK</description>
  </link>
  <results_reference>
    <citation>Burns J, Sivananthan MU, Ball SG, Mackintosh AF, Mary DA, Greenwood JP. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation. 2007 Apr 17;115(15):1999-2005. Epub 2007 Mar 26.</citation>
    <PMID>17389264</PMID>
  </results_reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2007</study_first_submitted>
  <study_first_submitted_qc>August 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2007</study_first_posted>
  <last_update_submitted>August 15, 2012</last_update_submitted>
  <last_update_submitted_qc>August 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leeds</investigator_affiliation>
    <investigator_full_name>Dr JP Greenwood</investigator_full_name>
    <investigator_title>Senior Lecturer</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Left Ventricular Hypertrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxonidine</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Bendroflumethiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

